Investigation of capsule interactions that promote antimicrobial peptide activity

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI159203-01

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia
  • Start & end year

    2021
    2023
  • Known Financial Commitments (USD)

    $194,615
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Bryan Davies
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF TEXAS AT AUSTIN
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary. The extracellular polysaccharide capsule of Klebsiella pneumoniae resists penetration by antimicrobials and protects the bacteria from the innate immune system. While capsule inhibits most host defense peptides and polymyxin antibiotics, a few amphipathic antimicrobial peptides have been identified that retain activity against capsulated K. pneumoniae. However, it is not known what enables some peptides to avoid sequestration by K. pneumoniae capsule while it effectively neutralizes most others. We have uncovered a mechanism that allows synthetic antimicrobial peptides to overcome capsule inhibition. Specific amino acid changes in inactive sequences enable peptides to bind, aggregate, and disrupt capsule layers, leaving K. peumoniae vulnerable to their membrane attack. Through this proposal we will 1) explore this new mechanism in innate immune host defense peptides that kill capsulated K. pneumoniae, and 2) characterize amino acid sequence and positional variations that promote activity towards capsulated bacteria. Our results will provide important insight into immune evasion by K. pneumoniae and other capsulated bacteria, and identify mechanistic principles will aid the development new therapeutic approaches to overcome the capsule barrier.